American Society of Hematology

Figure 1.

$ECV fraction is abnormally elevated in nearly all patients in our study (reference normal 20.8% ± 2.4% in children9and 25.9% ± 0.4% in adults14). (A) ECV was not different among children who started DMT at less than 6 years of age (SCA with early therapy, n = 20) or after (SCA no early therapy, n = 8). Datapoints from our cohort are overlayed in solid red circles or open circles. Three patients in our cohort did not receive any DMT. Solid green circles represent data points from Niss et al for comparison.1 (B) Starting DMT at an even earlier age (at less than 3 years of age) has no further protective effect, and the ECV of the 2 cohorts is comparable.$

ECV fraction is abnormally elevated in nearly all patients in our study (reference normal 20.8% ± 2.4% in children⁹^,and 25.9% ± 0.4% in adults¹⁴^,). (A) ECV was not different among children who started DMT at less than 6 years of age (SCA with early therapy, n = 20) or after (SCA no early therapy, n = 8). Datapoints from our cohort are overlayed in solid red circles or open circles. Three patients in our cohort did not receive any DMT. Solid green circles represent data points from Niss et al for comparison.¹ (B) Starting DMT at an even earlier age (at less than 3 years of age) has no further protective effect, and the ECV of the 2 cohorts is comparable.

This Feature Is Available To Subscribers Only